XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend
Dividend Declaration: XOMA Corp - 8.375% DP PFD B has declared a quarterly dividend of $0.5234 per share, maintaining the same amount as previous dividends, with a forward yield of 8.18%.
Payment Details: The dividend is payable on January 15 for shareholders recorded by January 3, with an ex-dividend date also set for January 3.
Trade with 70% Backtested Accuracy
Analyst Views on XOMAO
No data
About the author
XOMA Royalty Completes Acquisition of Generation Bio
- Acquisition Completion: XOMA Royalty has successfully completed its acquisition of Generation Bio, offering a cash price of $4.2913 per share along with a non-tradeable contingent value right, demonstrating the company's commitment to expanding in the biotechnology sector.
- Share Acceptance Rate: As of February 6, 2026, XOMA accepted 4,722,533 shares of Generation Bio, representing approximately 70% of its outstanding shares, satisfying the minimum tender condition and indicating market approval of the transaction.
- Post-Merger Outcome: Following the acquisition, Generation Bio has become a wholly owned subsidiary of XOMA, with all shares not validly tendered converting into cash rights, further solidifying XOMA's market position in biotechnology.
- Market Impact: This acquisition is expected to enhance XOMA's asset portfolio, creating new revenue opportunities for the future, while potentially boosting investor confidence in XOMA and driving its stock price upward.
XOMA Corp Announces $0.5234 Dividend for 8.375% DP Preferred Shares
Dividend Declaration: XOMA Corp has declared a quarterly dividend of $0.5234 per share, with a forward yield of 8.2%.
Payment Details: The dividend is payable on January 15 to shareholders of record as of January 2, with an ex-dividend date also set for January 2.
Acquisition Update: XOMA Royalty is set to acquire Generation Bio, indicating strategic growth moves.
Tender Offer Extension: XOMA has extended its tender offer for LAVA Therapeutics until October 17, reflecting ongoing investment activities.
XOMA Completes Acquisition of Mural Oncology at $2.035 per Share
- Acquisition Completed: XOMA Royalty has successfully completed its acquisition of Mural Oncology, with a cash consideration of $2.035 per share, marking a significant expansion in the biotech sector for the company.
- Shareholder Approval: The acquisition received approval from Mural shareholders, indicating market confidence in the transaction, which is expected to enhance XOMA's asset portfolio and future revenue potential.
- Legal Process Smooth: The acquisition was sanctioned by the Irish High Court, ensuring the legality and smooth execution of the transaction, providing XOMA with a solid legal foundation.
- Market Impact: Mural shares will cease trading on Nasdaq immediately following the completion of the acquisition, which is anticipated to positively influence XOMA's market performance and strengthen its competitive position in the biotech industry.
XOMA Royalty Announces Financial Results for Q3 and Year-to-Date 2025, Along with Recent Business Milestones
Business Development: XOMA Royalty has secured royalty interests in two partnered assets through its acquisition of LAVA Therapeutics and completed acquisitions of Turnstone Biologics and HilleVax, while also acting as a structuring agent for XenoTherapeutics' acquisition of ESSA Pharma.
Pipeline Advancements: Key developments include Zevra Therapeutics' submission of a Marketing Authorization Application for arimoclomol, Rezolute Bio's expected topline data announcement in December for its Phase 3 trial, and Gossamer Bio's anticipated results from its Phase 3 trial of seralutunib in February 2026.
Financial Performance: In the first nine months of 2025, XOMA Royalty reported $43.9 million in cash receipts, with a net income of $25.6 million, a significant improvement from net losses in the same period of 2024.
Cash Position and Future Outlook: As of September 30, 2025, XOMA Royalty had $130.6 million in cash and cash equivalents, with plans to leverage its growing portfolio for future revenue generation while maintaining a healthy cash balance.
XOMA Royalty Prolongs Tender Offer to Purchase LAVA Therapeutics N.V.
Tender Offer Extension: XOMA Royalty Corporation has extended its tender offer for LAVA Therapeutics' shares until October 17, 2025, allowing shareholders to receive cash and a contingent value right based on future proceeds from LAVA's partnered and unpartnered assets.
Acquisition Process: The acquisition is expected to close in Q4 2025, contingent on certain conditions including the tender of at least 80% of LAVA's shares and the adoption of specific resolutions by LAVA's shareholders.
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
Acquisition Announcement: XOMA Royalty Corporation has entered into a definitive share purchase agreement to acquire LAVA Therapeutics for between $1.16 and $1.24 per share in cash, along with a contingent value right representing 75% of the net proceeds from LAVA's partnered assets.
Transaction Details: The tender offer is expected to commence by August 15, 2025, with the closing anticipated in the fourth quarter of 2025, subject to conditions including shareholder approval and minimum share tendering requirements.
XOMA Royalty Completes Acquisition of Generation Bio
- Acquisition Completion: XOMA Royalty has successfully completed its acquisition of Generation Bio, offering a cash price of $4.2913 per share along with a non-tradeable contingent value right, demonstrating the company's commitment to expanding in the biotechnology sector.
- Share Acceptance Rate: As of February 6, 2026, XOMA accepted 4,722,533 shares of Generation Bio, representing approximately 70% of its outstanding shares, satisfying the minimum tender condition and indicating market approval of the transaction.
- Post-Merger Outcome: Following the acquisition, Generation Bio has become a wholly owned subsidiary of XOMA, with all shares not validly tendered converting into cash rights, further solidifying XOMA's market position in biotechnology.
- Market Impact: This acquisition is expected to enhance XOMA's asset portfolio, creating new revenue opportunities for the future, while potentially boosting investor confidence in XOMA and driving its stock price upward.
XOMA Corp Announces $0.5234 Dividend for 8.375% DP Preferred Shares
Dividend Declaration: XOMA Corp has declared a quarterly dividend of $0.5234 per share, with a forward yield of 8.2%.
Payment Details: The dividend is payable on January 15 to shareholders of record as of January 2, with an ex-dividend date also set for January 2.
Acquisition Update: XOMA Royalty is set to acquire Generation Bio, indicating strategic growth moves.
Tender Offer Extension: XOMA has extended its tender offer for LAVA Therapeutics until October 17, reflecting ongoing investment activities.
XOMA Completes Acquisition of Mural Oncology at $2.035 per Share
- Acquisition Completed: XOMA Royalty has successfully completed its acquisition of Mural Oncology, with a cash consideration of $2.035 per share, marking a significant expansion in the biotech sector for the company.
- Shareholder Approval: The acquisition received approval from Mural shareholders, indicating market confidence in the transaction, which is expected to enhance XOMA's asset portfolio and future revenue potential.
- Legal Process Smooth: The acquisition was sanctioned by the Irish High Court, ensuring the legality and smooth execution of the transaction, providing XOMA with a solid legal foundation.
- Market Impact: Mural shares will cease trading on Nasdaq immediately following the completion of the acquisition, which is anticipated to positively influence XOMA's market performance and strengthen its competitive position in the biotech industry.
XOMA Royalty Announces Financial Results for Q3 and Year-to-Date 2025, Along with Recent Business Milestones
Business Development: XOMA Royalty has secured royalty interests in two partnered assets through its acquisition of LAVA Therapeutics and completed acquisitions of Turnstone Biologics and HilleVax, while also acting as a structuring agent for XenoTherapeutics' acquisition of ESSA Pharma.
Pipeline Advancements: Key developments include Zevra Therapeutics' submission of a Marketing Authorization Application for arimoclomol, Rezolute Bio's expected topline data announcement in December for its Phase 3 trial, and Gossamer Bio's anticipated results from its Phase 3 trial of seralutunib in February 2026.
Financial Performance: In the first nine months of 2025, XOMA Royalty reported $43.9 million in cash receipts, with a net income of $25.6 million, a significant improvement from net losses in the same period of 2024.
Cash Position and Future Outlook: As of September 30, 2025, XOMA Royalty had $130.6 million in cash and cash equivalents, with plans to leverage its growing portfolio for future revenue generation while maintaining a healthy cash balance.
XOMA Royalty Prolongs Tender Offer to Purchase LAVA Therapeutics N.V.
Tender Offer Extension: XOMA Royalty Corporation has extended its tender offer for LAVA Therapeutics' shares until October 17, 2025, allowing shareholders to receive cash and a contingent value right based on future proceeds from LAVA's partnered and unpartnered assets.
Acquisition Process: The acquisition is expected to close in Q4 2025, contingent on certain conditions including the tender of at least 80% of LAVA's shares and the adoption of specific resolutions by LAVA's shareholders.
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
Acquisition Announcement: XOMA Royalty Corporation has entered into a definitive share purchase agreement to acquire LAVA Therapeutics for between $1.16 and $1.24 per share in cash, along with a contingent value right representing 75% of the net proceeds from LAVA's partnered assets.
Transaction Details: The tender offer is expected to commence by August 15, 2025, with the closing anticipated in the fourth quarter of 2025, subject to conditions including shareholder approval and minimum share tendering requirements.
